The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Open accessAbstract
BACKGROUND: Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β(2)-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β(2)-agonist salmeterol in preventing exacerbations of COPD. METHODS: In a 1-year, randomized, double-blind, double-dummy, parallel-group trial, we compared the effect of treatment with 18 μg of tiotropium once daily with that of 50 μg of salmeterol twice daily on the incidence of moderate or severe exacerbations in patients with moderate-to-very-severe COPD and a history of exacerbations in the preceding year. RESULTS: A total of 7376 patients were randomly assigned to and treated with tiotropium (3707 patients) or salmeterol (3669 patients). Tiotropium, as compared with salmeterol, increased the time to the first exacerbation (187 days vs. 145 days), with a 17% reduction in risk (hazard ratio, 0.83; 95% confidence interval [CI], 0.77 to 0.90; P<0.001). Tiotropium also increased the time to the first severe exacerbation (hazard ratio, 0.72; 95% CI, 0.61 to 0.85; P<0.001), reduced the annual number of moderate or severe exacerbations (0.64 vs. 0.72; rate ratio, 0.89; 95% CI, 0.83 to 0.96; P=0.002), and reduced the annual number of severe exacerbations (0.09 vs. 0.13; rate ratio, 0.73; 95% CI, 0.66 to 0.82; P<0.001). Overall, the incidence of serious adverse events and of adverse events leading to the discontinuation of treatment was similar in the two study groups. There were 64 deaths (1.7%) in the tiotropium group and 78 (2.1%) in the salmeterol group. CONCLUSIONS: These results show that, in patients with moderate-to-very-severe COPD, tiotropium is more effective than salmeterol in preventing exacerbations. (Funded by Boehringer Ingelheim and Pfizer; ClinicalTrials.gov number, NCT00563381.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
(1993) · PubMed · Cited by 3,827
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D. A., Agusti, A., MacNee, W., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909883 · Cited by 2,981
Donaldson, G. C. (2002) · Thorax · doi:10.1136/thorax.57.10.847 · Cited by 2,272
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805800 · Cited by 1,604
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Casaburi, R., Mahler, D. A., Jones, P. W., Wanner, A., San Pedro, G., ZuWallack, R. L., Menjoge, S. S., Serby, C. W., & Witek, T. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00269802 · Cited by 881
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Mahler, D. A., Donohue, J. F., Barbee, R. A., Goldman, M. D., Gross, N. J., Wisniewski, M. E., Yancey, S. W., Zakes, B. A., Rickard, K. A., & Anderson, W. H. (1999) · Chest · doi:10.1378/chest.115.4.957 · Cited by 520
Niewoehner, D. E., Rice, K., Cote, C., Paulson, D., Cooper, J. A. D., Korducki, L., Cassino, C., & Kesten, S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00007 · Cited by 436
Brusasco, V (2005) · Thorax · doi:10.1136/thx.2005.brusascolett · Cited by 431
Brusasco, V (2003) · Thorax · doi:10.1136/thorax.58.5.399 · Cited by 409
Dahl, R., Chung, K. F., Buhl, R., Magnussen, H., Nonikov, V., Jack, D., Bleasdale, P., Owen, R., Higgins, M., Kramer, B., et al. (2010) · Thorax · doi:10.1136/thx.2009.125435 · Cited by 273
RENNARD, S. I., ANDERSON, W., ZuWALLACK, R., BROUGHTON, J., BAILEY, W., FRIEDMAN, M., WISNIEWSKI, M., & RICKARD, K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.9903053 · Cited by 265
Cardiovascular events in patients with COPD: TORCH Study results
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Crim, C., Willits, L. R., Yates, J. C., Vestbo, J., et al. (2010) · Thorax · doi:10.1136/thx.2010.136077 · Cited by 207
Cardiovascular Safety of Tiotropium in Patients With COPD
Celli, B., Decramer, M., Leimer, I., Vogel, U., Kesten, S., & Tashkin, D. P. (2010) · Chest · doi:10.1378/chest.09-0011 · Cited by 184
Alternative Mechanisms for Long-Acting β2-Adrenergic Agonists in COPD
Johnson, M., & Rennard, S. I. (2001) · CHEST Journal · doi:10.1378/chest.120.1.258 · Cited by 156
Alternative mechanisms for tiotropium
Bateman, E. D., Rennard, S. I., Barnes, P. J., Dicpinigaitis, P. V., Gosens, R., Gross, N. J., Nadel, J. A., Pfeifer, M. A., Racké, K., Rabe, K. F., et al. (2009) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2009.06.002 · Cited by 124
Self-citationWithdrawal From Treatment as an Outcome in the ISOLDE Study of COPD
Calverley, P. M. A., Spencer, S., Willits, L. R., Burge, P. S., & Jones, P. (2003) · CHEST Journal · doi:10.1378/chest.124.4.1350 · Cited by 121
Cardiovascular Safety of Salmeterol in COPDa
Ferguson, G. T., Funck‐Brentano, C., Fischer, T., Darken, P. F., & Reisner, C. (2003) · CHEST Journal · doi:10.1378/chest.123.6.1817 · Cited by 106
Outpatient Management of Severe COPD
Niewoehner, D. E. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0912556 · Cited by 89
Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD
Briggs, D. D., Covelli, H. D., Lapidus, R. J., Bhattycharya, S., Kesten, S., & Cassino, C. (2005) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2005.02.013 · Cited by 88
Tiotropium HandiHaler® in the treatment of COPD: A safety review
Kesten, S., Celli, B., Decramer, M., Leimer, I., & Tashkin, D. (2009) · International Journal of COPD · doi:10.2147/copd.s4802 · Cited by 66
Health Care Reform and the Need for Comparative-Effectiveness Research
Mushlin, A. I., & Ghomrawi, H. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0912651 · Cited by 63
Methods for therapeutic trials in COPD: lessons from the TORCH trial
Keene, O. N., Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B. R., Ferguson, G. T., Jenkins, C. R., & Jones, P. (2009) · European Respiratory Journal · doi:10.1183/09031936.00122608 · Cited by 26
Choice of Bronchodilator Therapy for Patients with COPD
Wedzicha, J. A. (2011) · New England Journal of Medicine · doi:10.1056/nejme1013932 · Cited by 20
Cited by
Vogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201701-0218pp · Cited by 3,187
Self-citationQaseem, A., Wilt, T. J., Weinberger, S. E., Hanania, N. A., Criner, G., van der Molen, T., Marciniuk, D. D., Denberg, T., Schünemann, H., Wedzicha, W., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-3-201108020-00008 · Cited by 1,087
Chronic obstructive pulmonary disease
Rabe, K. F., & Watz, H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31222-9 · Cited by 960
Self-citationVogelmeier, C. F., Criner, G. J., Martinez, F. J., Anzueto, A., Barnes, P. J., Bourbeau, J., Celli, B. R., Chen, R., Decramer, M., Fabbri, L. M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00214-2017 · Cited by 881
Self-citationSuissa, S., Dell'Aniello, S., & Ernst, P. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201518 · Cited by 779
Metadata
- Authors
- Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Mölken, M. P. M. H., Beeh, K. M., Rabe, K. F., & Fabbri, L. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-24
- Volume
- 364
- Issue
- 12
- Pages
- 1093-1103
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096723137
- Cited by
- 684
- References
- 30
- FWCI
- 57.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.